REGENXBIO Announces New License Agreement with Pfizer for the Treatment of Friedreich's Ataxia Using NAV(R) AAV9 Vector

ROCKVILLE, Md., July 31, 2019 -- (Healthcare Sales & Marketing Network) -- REGENXBIO Inc. (Nasdaq: RGNX), a leading clinical-stage biotechnology company seeking to improve lives through the curative potential of gene therapy based on its proprietary NAV T... Biopharmaceuticals, Neurology, Licensing REGENXBIO, Pfizer, Friedreich's ataxia, movement disorder
Source: HSMN NewsFeed - Category: Pharmaceuticals Source Type: news